Comparison of the Prognostic and Predictive Utilities of the 21-Gene Recurrence Score Assay and Adjuvant! for Women with Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20

Lignende værker

• Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
  af: Mamounas, Eleftherios P., et al.
  Udgivet: (2010)
• Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP)
  af: Rastogi, Priya, et al.
  Udgivet: (2017)
• 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: Results from NSABP B-28/NRG Oncology
  af: Mamounas, Eleftherios P., et al.
  Udgivet: (2017)
• Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
  af: Pogue-Geile, Katherine L., et al.
  Udgivet: (2015)
• The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP)
  af: Wickerham, D. Lawrence, et al.
  Udgivet: (2008)